Q-omics provides the consensus-scored MYL6P4 profile across patient tissues and cancer cell-line models. MYL6P4 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MYL6P4 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, MYL6P4 RNA expression shows 6,007 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, and STAD as cancer lineages where MYL6P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL6P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL6P4 survival associations across molecular data types. MYL6P4 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL6P4 RNA expression–survival associations across cancer types. High MYL6P4 expression shows unfavorable associations in UVM, STAD, LUAD, BRCA, READ and DLBC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MYL6P4 RNA expression.
This table summarizes MYL6P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MYL6P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL6P4 shows lower tumor expression in STAD and PAAD and higher tumor expression in BRCA, KIRP, COAD and KIRC. The STAD box plot shows higher MYL6P4 RNA expression in normal versus tumor tissue (log2 FC = −0.241, t-test p = .006).
This table shows molecular features associated with MYL6P4 in patient tissues and cancer cell lines. In patient samples, MYL6P4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
